GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Enterprise Value

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Enterprise Value : ¥4,772 Mil (As of Jun. 23, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Shanghai Kaibao Pharmaceutical Co's Enterprise Value is ¥4,772 Mil. Shanghai Kaibao Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥335 Mil. Therefore, Shanghai Kaibao Pharmaceutical Co's EV-to-EBIT ratio for today is 14.23.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Shanghai Kaibao Pharmaceutical Co's Enterprise Value is ¥4,772 Mil. Shanghai Kaibao Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥335 Mil. Therefore, Shanghai Kaibao Pharmaceutical Co's EV-to-EBITDA ratio for today is 14.23.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Shanghai Kaibao Pharmaceutical Co's Enterprise Value is ¥4,772 Mil. Shanghai Kaibao Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,610 Mil. Therefore, Shanghai Kaibao Pharmaceutical Co's EV-to-Revenue ratio for today is 2.96.


Shanghai Kaibao Pharmaceutical Co Enterprise Value Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Enterprise Value Chart

Shanghai Kaibao Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,945.37 3,708.01 5,047.15 7,599.27 6,205.59

Shanghai Kaibao Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,025.25 6,602.17 6,454.36 6,205.59 5,484.51

Competitive Comparison of Shanghai Kaibao Pharmaceutical Co's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Kaibao Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Kaibao Pharmaceutical Co's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Kaibao Pharmaceutical Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Shanghai Kaibao Pharmaceutical Co's Enterprise Value falls into.



Shanghai Kaibao Pharmaceutical Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Shanghai Kaibao Pharmaceutical Co's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Shanghai Kaibao Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Kaibao Pharmaceutical Co  (SZSE:300039) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Shanghai Kaibao Pharmaceutical Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4771.750/335.281
=14.23

Shanghai Kaibao Pharmaceutical Co's current Enterprise Value is ¥4,772 Mil.
Shanghai Kaibao Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥335 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Shanghai Kaibao Pharmaceutical Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=4771.750/335.281
=14.23

Shanghai Kaibao Pharmaceutical Co's current Enterprise Value is ¥4,772 Mil.
Shanghai Kaibao Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥335 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Shanghai Kaibao Pharmaceutical Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4771.750/1610.161
=2.96

Shanghai Kaibao Pharmaceutical Co's current Enterprise Value is ¥4,772 Mil.
Shanghai Kaibao Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,610 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Kaibao Pharmaceutical Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Traded in Other Exchanges
N/A
Address
88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
Executives
Liu Shao Yong Supervisors
Ren Li Wang Secretary Dong
Zhang Tao Executives
Mu Jing Wei Director
Li Xiu Hai Directors, executives
Zhang Lian Xin Supervisors
Han Jing Independent director
Wang Guo Ming Directors, executives
Wang Chong Bang Executives
Liu Yi Shan Director
Li Qing Wei Independent director
Mu Lai An Director
Zhu Ying Jun Executives
Chang Qing Ling Supervisors
Zhang Peng Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines